Deutsche Bank analyst Emmanuel Papadakis maintained a Buy rating on Novartis AG (NOVN – Research Report) today and set a price target of ...

A registry study led by the University of Oulu examined the early-stage treatment of relapsing-remitting multiple sclerosis (MS) in Finland between 2013 and 2022.

Novartis is just months away from filing for ... and swelling that can last for weeks at a time and resist even very high doses of antihistamines, which are the first-line therapy of choice ...

Novartis is one of the world's top pharmaceutical companies, and along with neighbours Roche, the mainstay of Switzerland's centuries-long contribution to new medicines. Headquartered in Basel ...

with the lead indication for prevention of stroke and systemic embolism in patients with atrial fibrillationAcquisition adds a late-stage asset and is aligned with Novartis strategic focus ...

Strategic partnerships and ongoing research and development efforts are enhancing production efficiency and product quality ... by offering a product with high radionuclidic purity and superior ...

Commissions do not affect our editors' opinions or evaluations. The best high-yield savings account is Capital One 360 Performance Savings Account™, earning the top rating of 5.0 stars in our study.

The dynamics of the multiple system atrophy treatment market is anticipated to change during the forecast period as companies across the 7MM are diligently working towards the development of novel ...